Cargando…

Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective

Shewanella putrefaciens is a gramnegative, facultatively anaerobic, rod shaped bacterium. It belongs to the class of the Gammaproteobacteria and was first described in 1931. S. putrefaciens is part of the marine microflora and especially present in moderate and warm climates. The bacterium is a rare...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Stephanie, von Bonin, Simone, Schneider, Ralph, Krüger, Martin, Quick, Susanne, Schröttner, Percy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933709/
https://www.ncbi.nlm.nih.gov/pubmed/36817694
http://dx.doi.org/10.3389/fcimb.2022.1033639
_version_ 1784889728091291648
author Müller, Stephanie
von Bonin, Simone
Schneider, Ralph
Krüger, Martin
Quick, Susanne
Schröttner, Percy
author_facet Müller, Stephanie
von Bonin, Simone
Schneider, Ralph
Krüger, Martin
Quick, Susanne
Schröttner, Percy
author_sort Müller, Stephanie
collection PubMed
description Shewanella putrefaciens is a gramnegative, facultatively anaerobic, rod shaped bacterium. It belongs to the class of the Gammaproteobacteria and was first described in 1931. S. putrefaciens is part of the marine microflora and especially present in moderate and warm climates. The bacterium is a rare oppurtonistic human pathogen associated mainly with intra-abdominal as well as skin and soft tissue infections. However, it has also been reported in association with more severe diseases such as pneumonia, intracerebral and ocular infections and endocarditis. In these cases the clinical courses are often associated with underlying, predisposing diseases and risk factors. For successful treatment of S. putrefaciens, a combination of appropriate local therapy, e.g. surgical treatment or drainage, and antibiotic therapy should be performed. Since multiple resistances to antibiotics are described, the results of the antimicrobial susceptibility testing must be considered for effective therapy as well. Furthermore, a main challenge in clinical practice is the accurate microbiological identification, and especially the correct differentiation between S. putrefaciens and S. algae. Under certain circumstances, Shewanella-infections can have severe, sometimes even fatal consequences. Therefore, we decided to present the current state of knowledge as well as further aspects with regard to future diagnostics, therapy and research.
format Online
Article
Text
id pubmed-9933709
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99337092023-02-17 Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective Müller, Stephanie von Bonin, Simone Schneider, Ralph Krüger, Martin Quick, Susanne Schröttner, Percy Front Cell Infect Microbiol Cellular and Infection Microbiology Shewanella putrefaciens is a gramnegative, facultatively anaerobic, rod shaped bacterium. It belongs to the class of the Gammaproteobacteria and was first described in 1931. S. putrefaciens is part of the marine microflora and especially present in moderate and warm climates. The bacterium is a rare oppurtonistic human pathogen associated mainly with intra-abdominal as well as skin and soft tissue infections. However, it has also been reported in association with more severe diseases such as pneumonia, intracerebral and ocular infections and endocarditis. In these cases the clinical courses are often associated with underlying, predisposing diseases and risk factors. For successful treatment of S. putrefaciens, a combination of appropriate local therapy, e.g. surgical treatment or drainage, and antibiotic therapy should be performed. Since multiple resistances to antibiotics are described, the results of the antimicrobial susceptibility testing must be considered for effective therapy as well. Furthermore, a main challenge in clinical practice is the accurate microbiological identification, and especially the correct differentiation between S. putrefaciens and S. algae. Under certain circumstances, Shewanella-infections can have severe, sometimes even fatal consequences. Therefore, we decided to present the current state of knowledge as well as further aspects with regard to future diagnostics, therapy and research. Frontiers Media S.A. 2023-02-02 /pmc/articles/PMC9933709/ /pubmed/36817694 http://dx.doi.org/10.3389/fcimb.2022.1033639 Text en Copyright © 2023 Müller, von Bonin, Schneider, Krüger, Quick and Schröttner https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Müller, Stephanie
von Bonin, Simone
Schneider, Ralph
Krüger, Martin
Quick, Susanne
Schröttner, Percy
Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective
title Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective
title_full Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective
title_fullStr Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective
title_full_unstemmed Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective
title_short Shewanella putrefaciens, a rare human pathogen: A review from a clinical perspective
title_sort shewanella putrefaciens, a rare human pathogen: a review from a clinical perspective
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933709/
https://www.ncbi.nlm.nih.gov/pubmed/36817694
http://dx.doi.org/10.3389/fcimb.2022.1033639
work_keys_str_mv AT mullerstephanie shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective
AT vonboninsimone shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective
AT schneiderralph shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective
AT krugermartin shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective
AT quicksusanne shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective
AT schrottnerpercy shewanellaputrefaciensararehumanpathogenareviewfromaclinicalperspective